1.02
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th - The Manila Times
RenovoRx (NASDAQ: RNXT) CEO Shaun Bagai to join Canaccord MedTech Forum on Nov 20 - Stock Titan
Is RenovoRx Inc. stock dividend yield sustainableFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Intraday pattern recognizer results for RenovoRx Inc.2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
Is RenovoRx Inc. stock supported by innovation pipeline2025 Sector Review & Proven Capital Preservation Methods - newser.com
Tick level data insight on RenovoRx Inc. volatilityWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Can RenovoRx Inc. stock deliver consistent earnings growthTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com
Using AI based signals to follow RenovoRx Inc.2025 Sector Review & Safe Entry Point Alerts - newser.com
Is RenovoRx Inc. stock attractive for income investorsMarket Movers & Advanced Swing Trade Entry Plans - newser.com
Can machine learning forecast RenovoRx Inc. recoveryJuly 2025 Recap & Safe Capital Investment Plans - newser.com
Does RenovoRx Inc. fit your quant trading modelMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Will RenovoRx Inc. stock attract ESG investorsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
What analyst consensus says on RenovoRx Inc. stock2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Should I hold or sell RenovoRx Inc. stock in 20252025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
Why RenovoRx Inc. stock remains on watchlists2025 Dividend Review & Risk Managed Investment Strategies - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Evaluating RenovoRx Inc. with trendline analysisJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
First Patient Treated in RenovoCath Clinical Trial - Medical Product Outsourcing
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment - TipRanks
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update - TipRanks
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - The Manila Times
RenovoRx (Nasdaq: RNXT) to host Q3 2025 call; RenovoCath and Phase III TIGeR-PaC - Stock Titan
자본화:
|
볼륨(24시간):